131 related articles for article (PubMed ID: 8520501)
1. Allogeneic bone marrow transplantation for the treatment of multiple myeloma. An overview of published reports.
Cavo M; Benni M; Cirio TM; Gozzetti A; Tura S
Stem Cells; 1995 Aug; 13 Suppl 2():126-31. PubMed ID: 8520501
[TBL] [Abstract][Full Text] [Related]
2. [Intensive treatment of multiple myeloma].
Harousseau JL
Bull Acad Natl Med; 2003; 187(2):405-13; discussion 413-5. PubMed ID: 14556449
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic bone marrow transplantation in multiple myeloma.
Tura S; Cavo M
Hematol Oncol Clin North Am; 1992 Apr; 6(2):425-35. PubMed ID: 1582983
[TBL] [Abstract][Full Text] [Related]
4. High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma.
Cavo M; Bandini G; Benni M; Gozzetti A; Ronconi S; Rosti G; Zamagni E; Lemoli RM; Bonini A; Belardinelli A; Motta MR; Rizzi S; Tura S
Bone Marrow Transplant; 1998 Jul; 22(1):27-32. PubMed ID: 9678792
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy.
Ortega JJ; Díaz de Heredia C; Olivé T; Bastida P; Llort A; Armadans L; Torrabadella M; Massuet L
Haematologica; 2003 Mar; 88(3):290-9. PubMed ID: 12651268
[TBL] [Abstract][Full Text] [Related]
6. Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Lee CK; Barlogie B; Zangari M; Fassas A; Anaissie E; Morris C; Van Rhee F; Cottler-Fox M; Thertulien R; Muwalla F; Mazher S; Badros A; Tricot G
Bone Marrow Transplant; 2002 Dec; 30(12):873-8. PubMed ID: 12476279
[TBL] [Abstract][Full Text] [Related]
7. [Stem cell transplantation in multiple myeloma].
Fukuda S; Sunami K; Sezaki T
Gan To Kagaku Ryoho; 1999 Sep; 26(10):1407-14. PubMed ID: 10500527
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic bone marrow transplantation for multiple myeloma.
Ballester OF
Semin Oncol; 1993 Oct; 20(5 Suppl 6):67-71. PubMed ID: 8211218
[TBL] [Abstract][Full Text] [Related]
9. An update of prognostic factors for allogeneic bone marrow transplantation in multiple myeloma using matched sibling donors. European Group for Blood and Marrow Transplantation.
Gahrton G; Tura S; Ljungman P; Bladé J; Cavo M; De Laurenzi A; Façon T; Gratwohl A; Michallet M; Nikoskelainen J
Stem Cells; 1995 Aug; 13 Suppl 2():122-5. PubMed ID: 8520500
[TBL] [Abstract][Full Text] [Related]
10. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
11. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma.
Harousseau JL; Attal M; Divine M; Marit G; Leblond V; Stoppa AM; Bourhis JH; Caillot D; Boasson M; Abgrall JF
Stem Cells; 1995 Aug; 13 Suppl 2():132-9. PubMed ID: 8520502
[TBL] [Abstract][Full Text] [Related]
12. Advances in therapy of multiple myeloma: lessons from acute leukemia.
Barlogie B
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2605-13. PubMed ID: 10068262
[TBL] [Abstract][Full Text] [Related]
13. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
[TBL] [Abstract][Full Text] [Related]
14. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma.
Giralt S; Aleman A; Anagnostopoulos A; Weber D; Khouri I; Anderlini P; Molldrem J; Ueno NT; Donato M; Korbling M; Gajewski J; Alexanian R; Champlin R
Bone Marrow Transplant; 2002 Sep; 30(6):367-73. PubMed ID: 12235521
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow up of patients with multiple myeloma after high-dose chemotherapy and allogeneic stem cell transplantation.
Rabitsch W; Prinz E; Ackermann J; Wöhrer S; Kaufmann H; Seidl S; Keil F; Kalhs P; Greinix H; Gisslinger H; Leitner G; Drach J
Eur J Haematol; 2004 Jan; 72(1):26-31. PubMed ID: 14962259
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect.
Le Blanc R; Montminy-Métivier S; Bélanger R; Busque L; Fish D; Roy DC; Kassis J; Boileau J; Lavallée R; Bélanger D; Letendre F; Hébert J; Sauvageau G; Perreault C; Roy J
Bone Marrow Transplant; 2001 Nov; 28(9):841-8. PubMed ID: 11781644
[TBL] [Abstract][Full Text] [Related]
17. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic transplantation for multiple myeloma: late relapse may occur as localised lytic lesion/plasmacytoma despite ongoing molecular remission.
Byrne JL; Fairbairn J; Davy B; Carter IG; Bessell EM; Russell NH
Bone Marrow Transplant; 2003 Feb; 31(3):157-61. PubMed ID: 12621475
[TBL] [Abstract][Full Text] [Related]
19. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.
Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N
Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134
[TBL] [Abstract][Full Text] [Related]
20. [Indications, technique and risks in bone marrow transplantation in adulthood].
Heyll A; Söhngen D; Minning H; Meckenstock G; Aul C; Schneider W
Praxis (Bern 1994); 1996 Mar; 85(12):378-86. PubMed ID: 8643901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]